A minireview of 1, 2, 3‐triazole hybrids with O‐heterocycles as leads in medicinal chemistry. (11th October 2021)
- Record Type:
- Journal Article
- Title:
- A minireview of 1, 2, 3‐triazole hybrids with O‐heterocycles as leads in medicinal chemistry. (11th October 2021)
- Main Title:
- A minireview of 1, 2, 3‐triazole hybrids with O‐heterocycles as leads in medicinal chemistry
- Authors:
- Saroha, Bhavna
Kumar, Gourav
Kumar, Ramesh
Kumari, Meena
Kumar, Suresh - Abstract:
- Abstract: Over the past few decades, the dynamic progress in the synthesis and screening of heterocyclic compounds against various targets has made a significant contribution in the field of medicinal chemistry. Among the wide array of heterocyclic compounds, triazole moiety has attracted the attention of researchers owing to its vast therapeutic potential and easy preparation via copper and ruthenium‐catalyzed azide‐alkyne cycloaddition reactions. Triazole skeletons are found as major structural components in a different class of drugs possessing diverse pharmacological profiles including anti‐cancer, anti‐bacterial, anti‐fungal, anti‐viral, anti‐oxidant, anti‐inflammatory, anti‐diabetic, anti‐tubercular, and anti‐depressant among various others. Furthermore, in the past few years, a significantly large number of triazole hybrids were synthesized with various heterocyclic moieties in order to gain the added advantage of the improved pharmacological profile, overcoming the multiple drug resistance and reduced toxicity from molecular hybridization. Among these synthesized triazole hybrids, many compounds are available commercially and used for treating different infections/disorders like tazobactam and cefatrizine as potent anti‐bacterial agents while isavuconazole and ravuconazole as anti‐fungal activities to name a few. In this review, we will summarize the biological activities of various 1, 2, 3‐triazole hybrids with copious oxygen‐containing heterocycles as leadAbstract: Over the past few decades, the dynamic progress in the synthesis and screening of heterocyclic compounds against various targets has made a significant contribution in the field of medicinal chemistry. Among the wide array of heterocyclic compounds, triazole moiety has attracted the attention of researchers owing to its vast therapeutic potential and easy preparation via copper and ruthenium‐catalyzed azide‐alkyne cycloaddition reactions. Triazole skeletons are found as major structural components in a different class of drugs possessing diverse pharmacological profiles including anti‐cancer, anti‐bacterial, anti‐fungal, anti‐viral, anti‐oxidant, anti‐inflammatory, anti‐diabetic, anti‐tubercular, and anti‐depressant among various others. Furthermore, in the past few years, a significantly large number of triazole hybrids were synthesized with various heterocyclic moieties in order to gain the added advantage of the improved pharmacological profile, overcoming the multiple drug resistance and reduced toxicity from molecular hybridization. Among these synthesized triazole hybrids, many compounds are available commercially and used for treating different infections/disorders like tazobactam and cefatrizine as potent anti‐bacterial agents while isavuconazole and ravuconazole as anti‐fungal activities to name a few. In this review, we will summarize the biological activities of various 1, 2, 3‐triazole hybrids with copious oxygen‐containing heterocycles as lead compounds in medicinal chemistry. This review will be very helpful for researchers working in the field of molecular modeling, drug design and development, and medicinal chemistry. Abstract : Triazole hybrids are the lead compound for the present‐day discoveries in medicinal chemistry. This mini‐review briefly summarizes the recently developed active hybrids of triazole with O‐heterocyclic. SAR is also discussed that set up the direction for the design and development of triazole hybrids with high efficiency against both drug‐resistant pathogens and drug sensitivity. … (more)
- Is Part Of:
- Chemical biology & drug design. Volume 100:Number 6(2022)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 100:Number 6(2022)
- Issue Display:
- Volume 100, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 100
- Issue:
- 6
- Issue Sort Value:
- 2022-0100-0006-0000
- Page Start:
- 843
- Page End:
- 869
- Publication Date:
- 2021-10-11
- Subjects:
- 1, 2, 3‐triazole -- biological activities -- hybrid compounds -- oxygen heterocycles -- structure‐activity relationship
Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.13966 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24621.xml